PBAC's latest decision on Pemetrexed: Recommended (2023). Considered for Patients with malignant pleural mesothelioma or locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
6
first 2007
Submissions
6
2007 → 2023
Eligible population
Patients with malignant pleural mesothelioma or locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology, currently treated with pemetrexed powder for injection.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
pemetrexed powder for injection (100 mg, 500 mg, and 1000 mg)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as pemetrexed solutions for injection are not expected to provide a substantial and clinically relevant improvement in efficacy or reduction of toxicity over currently listed forms.
ICER (historical)
$15k/QALY–$75k/QALY across 3 submissions (2007–2010) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2007: Recommended with restriction · Authority Required — ICER $75k/QALY
Mar 2009: Recommended with restriction · Authority Required — ICER $75k/QALY